Effect of the PPAR-alpha L162V polymorphism on the cardiovascular disease risk factor in response to n-3 polyunsaturated fatty acids

Journal of Nutrigenetics and Nutrigenomics

Volumn 1, Issue 4, 2008, Pages 205-212

  Caron Dorval, Dominique ^a,b,c   Paquet, Pascale ^a   Paradis, Ann Marie ^a,b,c   Rudkowska, Iwona ^a,b,c   Lemieux, Simone ^b,c   Couture, Patrick ^a   Vohl, Marie Claude ^a,b,c  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cardiovascular disease risk factors; Fatty acids; n 3; Nutrigenetics; Peroxisome proliferator activated receptor

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; FAT; FISH OIL; GLUCOSE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMOZYGOTE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW FAT DIET; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; RISK FACTOR; STATISTICAL SIGNIFICANCE; SUPPLEMENTATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AMINO ACID SUBSTITUTION; CARDIOVASCULAR DISEASES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUCINE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; RISK FACTORS; VALINE; YOUNG ADULT;

EID: 45749121129     PISSN: 16616499     EISSN: 16616758     Source Type: Journal    
DOI: 10.1159/000137555     Document Type: Article

References (60)

1. Lewis A, Lookinland S, Beckstrand RL, Tiedeman ME: Treatment of hypertriglyceridemia with omega-3 fatty acids: a systematic review. J Am Acad Nurse Pract 2004;16:384-395.
2. Hopkins PN: Effects of dietary cholesterol on serum cholesterol: a meta-analysis and review. Am J Clin Nutr 1992;55:1060-1070.
3. Masson LF, McNeill G: The effect of genetic variation on the lipid response to dietary change: recent findings. Curr Opin Lipidol 2005;16:61-67.
4. Davignon J, Cohn JS, Mabile L, Bernier L: Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta 1999;286:115-143.
5. Paradis AM, Fontaine-Bisson B, Bosse Y, Robitaille J, Lemieux S, Jacques H, Lamarche B, Tchernof A, Couture P, Vohl MC: The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. Am J Clin Nutr 2005;81:523-530.
6. Tai ES, Corella D, Demissie S, Cupples LA, Coltell O, Schaefer EJ, Tucker KL, Ordovas JM: Framingham heart study: polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr 2005;135:397-403.
7. Uthurralt J, Gordish-Dressman H, Bradbury M, Tesi-Rocha C, Devaney J, Harmon B, Reeves EK, Brandoli C, Hansen BC, Seip RL, Thompson PD, Price TB, Angelopoulos TJ, Clarkson PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Gordon PM, Hoffman EP: PPARalpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med Genet 2007:16:55.
8. Vohl MC, Lepage P, Gaudet D, Brewer CG, Bétard C, Perron P, Houde G, Cellier C, Faith JM, Despés JP, Morgan K, Hudson TJ: Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000;41:945-952.
9. Sampath H, Ntambi JM: Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr 2005;25:317-340.
10. Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, Gonzalez FJ: The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 2000;10:321-333.
11. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
12. Goulet J, Nadeau G, Lapointe A, Lamarche B, Lemieux S: Validity and reproducibility of an interviewer-administered food frequency questionnaire for healthy French-Canadian men and women. Nutr J 2004;3:13.
13. Taylor HL, Jacobs DR Jr, Schucker B, Knudsen J, Leon AS, Debacker G: A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 1978;31:741-755.
14. Callaway CW: CWBC Standardization of Anthropometric Measurements. The Airlie (VA) Consensus Conference. Champaign, Human Kinetics Publishers, 1988.
15. McNamara JR, Schaefer EJ: Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987;166:1-8.
16. Burstein M, Samaille J: On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins. Clin Chim Acta 1960;5:609.
17. Albers JJ, Warnick GR, Wiebe D, King P, Steiner P, Smith L, Breckenridge C, Chow A, Kuba K, Weidman S, Arnett H, Wood P, Shlagenhaft A: Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin Chem 1978;24:853-856.
18. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
19. Laurell CB: Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966;15:45-52.
20. Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Després JP, Lamarche B: Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001;161:2474-2480.
21. Desbuquois B, Aurbach GD: Use of polyethylene glycol to separate free and antibodybound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 1971;33:732-738.
22. Richterich R, Dauwalder H: Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method. Schweiz Med Wochenschr 1971;101:615-618.
23. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
24. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-2093.
25. Balk EM, Horsley TA, Newberry SJ, Lichtenstein AH, Yetley EA, Schachter HM, Moher D, MacLean CH, Lau J: A collaborative effort to apply the evidence-based review process to the field of nutrition: challenges, benefits, and lessons learned. Am J Clin Nutr 2007;85:1448-1456.
26. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J: Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006;189:19-30.
27. Jump DB: Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 2002;13:155-164.
28. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-550.
29. Sampath H, Ntambi JM: Polyunsaturated fatty acid regulation of gene expression. Nutr Rev 2004;62:333-339.
30. Flavell DM, Pineda T, I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE: Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 2000;43:673-680.
31. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15:5336-5348.
32. Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge E, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Najib J, Fruchart JC: Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 2003;278:17982-17985.
33. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J: Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995;95:705-712.
34. Fruchart JC, Duriez P: Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 2006;42:39-64.
35. Gervois P, Torra IP, Fruchart JC, Staels B: Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 2000;38:3-11.
36. Bosse Y, Pascot A, Dumont M, Brochu M, Prud'homme D, Bergeron J, Després JP, Vohl MC: Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genet Med 2002;4:311-315.
37. Fruchart JC, Duriez P, Staels B: Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999;10:245-257.
38. Sessler AM, Ntambi JM: Polyunsaturated fatty acid regulation of gene expression. J Nutr 1998;128:923-926.
39. Gray-Donald K, Jacobs-Starkey L, Johnson-Down L: Food habits of Canadians: reduction in fat intake over a generation. Can J Public Health 2000;91:381-385.
40. DeLany JP, Vivian VM, Snook JT, Anderson PA: Effects of fish oil on serum lipids in men during a controlled feeding trial. Am J of Clin Nutr 1990;52:477-485.
41. Silva JM, Souza I, Silva R, Tavares P, Teixeira F, Silva PS: The triglyceride lowering effect of fish oils is affected by fish consumption. Int J Cardiol 1996;57:75-80.
42. Brox J, Olaussen K, Osterud B, Elvevoll EO, Bjørnstad E, Brattebøg G, Iversen H: A longterm seal- and cod-liver-oil supplementation in hypercholesterolemic subjects. Lipids 2001;36:7-13.
43. Eritsland J, Arnesen H, Seljeflot I, Høstmark AT: Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease. Am J Clin Nutr 1995;61:831-836.
44. Mori TA, Beilin LJ: Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004;6:461-467.
45. Calder PC: n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505S-1519S.
46. Couve AO, Koenig C, Santos MJ: Induction of peroxisomal enzymes and a 64-kDa peptide in cultured mouse macrophages treated with clofibrate. Exp Cell Res 1992;202:541-544.
47. von Schacky C: The role of omega-3 fatty acids in cardiovascular disease. Curr Atheroscler Rep 2003;5:139-145.
48. Ringbom T, Huss U, Stenholm A, Flock S, Skattebøl L, Perera P, Bohlin L: Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod 2001;64:745-749.
49. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB: Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003;108:155-160.
50. Okopien B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieli?ski M, Labuzek K, Herman ZS: The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 2004;176:327-335.
51. Empen K, Frost RJ, Geiss HC, Otto C, Parhofer KG: Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial. Cardiovasc Diabetol 2003;2:17.
52. Okapcova J, Gabor D: The levels of soluble adhesion molecules in diabetic and nondiabetic patients with combined hyperlipoproteinemia and the effect of ciprofibrate therapy. Angiology 2004;55:629-639.
53. Lopez-Garcia E, Schulze MB, Manson JE, Meigs JB, Albert CM, Rifai N, Willett WC, Hu FB: Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr 2004;134:1806-1811.
54. Yoneyama S, Miura K, Sasaki S, Yoshita K, Morikawa Y, Ishizaki M, Kido T, Naruse Y, Nakagawa H: Dietary intake of fatty acids and serum C-reactive protein in Japanese. J Epidemiol 2007;17:86-92.
55. Madsen T, Schmidt EB, Christensen JH: The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure. J Ren Nutr 2007;17:258-263.
56. Geelen A, Brouwer IA, Schouten EG, Kluft C, Katan MB, Zock PL: Intake of n-3 fatty acids from fish does not lower serum concentrations of C-reactive protein in healthy subjects. Eur J Clin Nutr 2004;58:1440-1442.
57. Vega-Lopez S, Kaul N, Devaraj S, Cai RY, German B, Jialal I: Supplementation with omega3 polyunsaturated fatty acids and allrac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. Metabolism 2004;53:236-240.
58. Browning LM, Krebs JD, Moore CS, Mishra GD, O'Connell MA, Jebb SA: The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes Metab 2007;9:70-80.
59. Basu A, Devaraj S, Jialal I: Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol 2006;26:995-1001.
60. Gotto AM, Jr: Role of C-reactive protein in coronary risk reduction: focus on primary prevention. Am J Cardiol 2007;99:718-725.